 |
|
Enzyme inhibitor produces stable disease in patients with advanced solid cell cancers
November 08, 2006Phase II trials initiated
Prague, Czech Republic: Preliminary trials of a MEK enzyme inhibitor have shown that it is capable of producing long-lasting stable disease in patients with advanced solid cancers. Tests showed that the drug inhibited key targets in the patients' tumours, and now it is being tested in phase II clinical trials.
Professor Alex Adjei told the EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Prague today (Wednesday 8 November) that the drug AZD6244 (ARRY-142886) [2] inhibited MEK1/2 - an enzyme that plays an important role in the Ras/Raf/MEK/ERK cell signalling pathway, which regulates cell proliferation and survival. Activation of this pathway has been implicated in a number of cancers, including lung, pancreatic, colon, melanoma and thyroid cancer.
"Laboratory studies have shown that AZD6244 has an effect on human tumours at nanomolar concentrations, and the first part of the phase I clinical trial has determined the maximum tolerated dose and the safety of the compound. Results from this second part of the trial demonstrate that a dose of 100mg of AZD6244 is well tolerated, produces a high incidence of long-lasting stable disease, and is associated with a profound inhibition of the cell signalling protein pERK and a reduction in cell proliferation - which indicates that the drug is working against the tumours," said Prof Adjei, who was professor of oncology at the Mayo Clinic, Rochester, USA, before moving in October to be the senior vice-president for clinical research and chair of the Department of Medicine at the Roswell Park Cancer Institute, Buffalo, USA.
Prof Adjei and his colleagues at the Mayo Clinic, University of Colorado Health Sciences Center and Fox Chase Cancer Center recruited into the second part of the trial 34 patients with advanced cancers, including melanoma, breast, lung and colorectal cancers. Approximately 40% of the patients had melanoma. The researchers were particularly interested in this tumour type because a large proportion harbour B-Raf mutations, and tumours with these mutations may be highly sensitive to MEK inhibitors.
The patients were randomised to receive 100 or 200mg doses, twice a day for 28-day cycles. The larger dose proved to be too high for continuous dosing due to adverse side effects, but the smaller dose was well tolerated over a prolonged period.
The researchers tested biopsy tissue taken from the patients both before and after dosing. They found that the pERK protein was reduced by 77%. They also looked at another protein, Ki-67, which is used as a marker for cell proliferation. After dosing, there was a reduction in Ki-67 in nine out of 20 patients, and in five of those nine patients the reduction was at least 50% or more.
"We found that after 15 days of dosing, AZD6244 continued to inhibit pERK at times when concentrations of the drug in the blood were at their lowest levels between doses. At the lowest concentration, 400 nanograms of the compound per microlitre of plasma still corresponded to a 35-44% inhibition of pERK," said Prof Adjei.
Overall, 39 of 57 patients completed at least one cycle of treatment with AZD6244. After completion of the second cycle, 19 (49%) had stable disease, and nine of these patients (six melanoma, one each of breast cancer, non-small cell lung cancer and medullary thyroid cancer) remained stable for five or more months (range, 5-14+ months; median, 6 months). Two patients, one with thyroid cancer and the other with melanoma, continue to receive treatment with AZD6244 after one year. Sixteen of the 20 patients with melanoma completed at least one cycle of treatment. Twelve had stable disease after completion of cycle two, with stable disease persisting for at least five months in six patients (range, 5-13+ months; median, 6.5 months).
Prof Adjei said: "This drug shows initial promising results. It appears to be able to target cancers with over-activation of MEK and associated cell signalling pathways in an efficient manner. Furthermore, it is easy to give to patients as it comes in an oral formulation that can be swallowed. As a result, a number of phase II clinical trials have been initiated in patients with melanoma, pancreatic, lung and colon cancers."
European Organisation for Research and Treatment of Cancer
"Laboratory studies have shown that AZD6244 has an effect on human tumours at nanomolar concentrations, and the first part of the phase I clinical trial has determined the maximum tolerated dose and the safety of the compound. Results from this second part of the trial demonstrate that a dose of 100mg of AZD6244 is well tolerated, produces a high incidence of long-lasting stable disease, and is associated with a profound inhibition of the cell signalling protein pERK and a reduction in cell proliferation - which indicates that the drug is working against the tumours," said Prof Adjei, who was professor of oncology at the Mayo Clinic, Rochester, USA, before moving in October to be the senior vice-president for clinical research and chair of the Department of Medicine at the Roswell Park Cancer Institute, Buffalo, USA.
Prof Adjei and his colleagues at the Mayo Clinic, University of Colorado Health Sciences Center and Fox Chase Cancer Center recruited into the second part of the trial 34 patients with advanced cancers, including melanoma, breast, lung and colorectal cancers. Approximately 40% of the patients had melanoma. The researchers were particularly interested in this tumour type because a large proportion harbour B-Raf mutations, and tumours with these mutations may be highly sensitive to MEK inhibitors.
The patients were randomised to receive 100 or 200mg doses, twice a day for 28-day cycles. The larger dose proved to be too high for continuous dosing due to adverse side effects, but the smaller dose was well tolerated over a prolonged period.
The researchers tested biopsy tissue taken from the patients both before and after dosing. They found that the pERK protein was reduced by 77%. They also looked at another protein, Ki-67, which is used as a marker for cell proliferation. After dosing, there was a reduction in Ki-67 in nine out of 20 patients, and in five of those nine patients the reduction was at least 50% or more.
"We found that after 15 days of dosing, AZD6244 continued to inhibit pERK at times when concentrations of the drug in the blood were at their lowest levels between doses. At the lowest concentration, 400 nanograms of the compound per microlitre of plasma still corresponded to a 35-44% inhibition of pERK," said Prof Adjei.
Overall, 39 of 57 patients completed at least one cycle of treatment with AZD6244. After completion of the second cycle, 19 (49%) had stable disease, and nine of these patients (six melanoma, one each of breast cancer, non-small cell lung cancer and medullary thyroid cancer) remained stable for five or more months (range, 5-14+ months; median, 6 months). Two patients, one with thyroid cancer and the other with melanoma, continue to receive treatment with AZD6244 after one year. Sixteen of the 20 patients with melanoma completed at least one cycle of treatment. Twelve had stable disease after completion of cycle two, with stable disease persisting for at least five months in six patients (range, 5-13+ months; median, 6.5 months).
Prof Adjei said: "This drug shows initial promising results. It appears to be able to target cancers with over-activation of MEK and associated cell signalling pathways in an efficient manner. Furthermore, it is easy to give to patients as it comes in an oral formulation that can be swallowed. As a result, a number of phase II clinical trials have been initiated in patients with melanoma, pancreatic, lung and colon cancers."
European Organisation for Research and Treatment of Cancer
Enzyme Inhibitor Current Events and Enzyme Inhibitor News RSSExperimental treatment halts hypoxic-ischemic brain injury in newborns
Inhibiting an enzyme in the brains of newborns suffering from oxygen and blood flow deprivation stops a type of brain damage that is a leading cause of cerebral palsy, mental retardation and death, according to researchers at Cincinnati Children's Hospital Medical Center.
Pitt team finds molecule that regulates heart size by using zebrafish screening model
Using zebrafish, researchers at the University of Pittsburgh have identified and described an enzyme inhibitor that allows them to increase the number of cardiac progenitor cells and therefore influence the size of the developing heart.
Novel enzyme inhibitor paves way for new cancer drug
Combining natural organic atoms with metal complexes, scientists at The Wistar Institute have developed a new type of enzyme inhibitor capable of blocking a biochemical pathway that plays a key role in cancer development.
Chronic kidney disease rises while most people with the condition remain unaware
A growing number of Americans have chronic kidney disease, but most remain unaware of it, hampering efforts to prevent irreversible kidney failure requiring dialysis or a transplant.
Scientists discover way to block growth of prostate cancer cells
Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer.
Pest control research leads to pain control discovery
A newly discovered enzyme inhibitor, identified by researchers originally looking for biological pest controls, may lead to pain relief for sufferers of arthritis and other inflammatory diseases.
Polycystic kidney disease
The National Institutes of Health (NIH) and the PKD Foundation have launched two treatment trials for autosomal dominant polycystic kidney disease (ADPKD).
Defeating the 'superpests'
Scientists have developed a new technique that makes pesticides more effective by removing insects' ability to exhibit resistance.
Blood pressure treatment could cut risk of strokes and heart attacks
A new treatment strategy for hypertension can cut the risk of strokes by around 25 percent and coronary events by around 15 percent according to the preliminary results of a major international trial announced at the American College of Cardiology Late Breaking Clinical Trials II Meeting in Orlando today.
Success of new treatment halts international blood pressure drug trial
An international trial comparing blood-pressure lowering treatments has been stopped early due to the significantly better performance of one of the treatments in the trial.
More Enzyme Inhibitor Current Events and Enzyme Inhibitor News Articles
 |
Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists (Methods of Biochemical Analysis) by Robert A. Copeland (Author) Vital information for discovering and optimizing new drugs "Understanding the data and the experimental details that support it has always been at the heart of good science and the assumption challenging process that leads from good science to drug discovery. This book helps medicinal chemists and pharmacologists to do exactly that in the realm of enzyme inhibitors." -Paul S. Anderson, PhD This publication provides readers with a thorough understanding of enzyme-inhibitor evaluation to assist them in their efforts to discover and optimize novel drug therapies. Key topics such as competitive, noncompetitive, and uncompetitive inhibition, slow binding, tight binding, and the use of Hill coefficients to study reaction stoichiometry are all presented. Examples of key... |
 |
Bromelain 2000 GDU/Gram, 500 mg, 60 Tablets by Bromelain 2000 GDU/Gram, 500 mg, 60 Tablets - Provided by Physician Formulas Bromelain is an enzyme from the pineapple plant which accelerates the breakdown of proteins. It is active in a wide pH range and can function in the acidic environment of the stomach. Bromelain is a combination of several protein-digesting enzymes along with peroxidase, acid phosphatase, protease inhibitors, and calcium. Bromelain is most often used to help digestion and help reduce inflammation. |
 |
Organic Chemistry of Enzyme-Catalyzed Reactions, Revised Edition, Second Edition by Richard B. Silverman Ph.D Organic Chemistry (Author) The Organic Chemistry of Enzyme-Catalyzed Reactions is not a book on enzymes, but rather a book on the general mechanisms involved in chemical reactions involving enzymes. An enzyme is a protein molecule in a plant or animal that causes specific reactions without itself being permanently altered or destroyed. This is a revised edition of a very successful book, which appeals to both academic and industrial markets. Illustrates the organic mechanism associated with each enzyme-catalyzed reaction Makes the connection between organic reaction mechanisms and enzyme mechanisms Compiles the latest information about molecular mechanisms of enzyme reactions Accompanied by clearly drawn structures, schemes, and... |
 |
Design of Caspase Inhibitors as Potential Clinical Agents (Crc Enzyme Inhibitors) by Tom O'Brien (Editor), Steven D. Linton (Editor) Presents the Therapeutic Potential for Caspase Inhibitors: Present and Future Caspases represent one of the most specific protease families described to date. These extremely important enzymes are crucial to the destruction of aberrant cells – the body’s self-protection mechanism for warding off the growth of abnormal cells, many of which can promote cancer. Design of Caspase Inhibitors as Potential Clinical Agents introduces cutting-edge evidence regarding caspases’ role in pro-inflammatory responses. New research now shows that the inhibition of caspase function is a critical component for the treatment of many diseases, including:
|
 |
ProntoPass Naplex Review Liver Enzymes Poster by ProntoPass Solutions Liver Enzymes 11" x 17" Poster. Great visual adjunct to regular ProntoPass® QUICKCARDS® Naplex® Review study material. Visualize the material and burn it into your brain. Evolutionary educational change, revolutionary results. Liver Enzymes is important to know for NAPLEX®. Printed on both sides. ProntoPass® - the prescription for success. |
|
Cancer and the Search for Selective Biochemical Inhibitors, Second Edition by E.J. Hoffman (Author) The world of medicine has become splintered into two factions, that of orthodoxy and its counterpart, alternative or complementary medicine. A problem with alternative medicine is, of course, that of anecdote and hearsay. The solution: the disclosure, in an unassailable fashion, of the underlying biochemical principles for alternative cancer therapies. Cancer and the Search for Selective Biochemical Inhibitors, Second Edition delineates the underlying biochemical principles for alternative cancer therapies. Completely revised and updated, this edition includes coverage of the link between concepts and practices of alternative and conventional medicine. The author examines anticancer plant substances and other alternatives such as Vitamin C, essiac tea, shark cartilage, and cat’s... | |
 |
Enzymes and Their Inhibitors: Drug Development (Enzyme Inhibitors) by H. John Smith (Editor), Claire Simons (Editor) Focusing on the development of enzyme inhibitors as therapeutic drugs, this textbook provides a concise overview of the chemistry of major types of enzymes and their inhibitors.The opening chapters introduce the reader to the structure, functions, mechanisms and kinetics of enzymes, including the use of enzymes as disease markers, analytical reagents and their use in industrial processes. Subsequent chapters discuss the different types of enzyme inhibitors and the basic principles involved in developing them into an effective drug, from discovery of the lead compound to their use in the clinic. An extremely useful text for all students of pharmacy and medicinal chemistry. |
 |
Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications (Wiley Series in Drug Discovery and Development) by Binghe Wang (Author), Claudiu T. Supuran (Editor), Jean-Yves Winum (Editor) Brings together functional and structural informationrelevant to the design of drugs targeting zinc enzymes The second most abundant transition element in living organisms, zinc spans all areas of metabolism, with zinc-containing proteins offering both established and potential drug targets. Drug Design of Zinc-Enzyme Inhibitors brings together functional and structural information relevant to these zinc-containing targets. With up-to-date overviews of the latest developments field, this unique and comprehensive text enables readers to understand zinc enzymes and evaluate them in a drug design context. With contributions from the leaders of today's research, Drug Design of Zinc-Enzyme Inhibitors covers such key topics as: Major drug targets like... |
 |
Protein Misfolding in Neurodegenerative Diseases: Mechanisms and Therapeutic Strategies (Enzyme Inhibitors) by H. John Smith (Editor), Claire Simons (Editor), Robert D. E. Sewell (Editor) Research focused on protein folding, misfolding, and aggregation is leading to major advances across biochemistry and medicine. The elucidation of a folding code is proving to be of extreme importance in the postgenomic era, where a number of orphan genes have been identified for which no clear function has yet been established. This research is starting to shed light on the molecular and biochemical basis of a number of neurodegenerative diseases of dramatic impact. Protein Misfolding in Neurodegenerative Diseases: Mechanisms and Therapeutic Strategies addresses key issues concerning protein misfolding and aggregation in neurodegenerative diseases. Building on recent developments, including the recognition of protein misfolding as both a marker and a causal agent, the text presents... |
 |
Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents (Crc Enzyme Inhibitors) by Paul J. Smith (Editor), Eddy W. Yue (Editor) One of the few books to cover all aspects of cyclin-dependent kinases (CDKs), Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents provides an overview of CDKs as molecular and functional entities, their involvement in different disease processes, and their potential for pharmacological modulation. With contributions from the top international researchers in the field, the book takes a contemporary approach to study the importance of rational drug design and knowledge-based therapeutics in relation to CDKs. The first two sections of the book discuss the integration of cell cycle control pathways, opportunities for targeting, targets of inhibitors, and the evaluation of CDK inhibitors, exploring topics such as the in vivo function of CDKs in normal homeostasisand tumor... |
| © 2009 BrightSurf.com |